Endocrine News Podcast Endocrine Society

In a special episode, we discuss a complex, rare disease, fibrodysplasia ossificans progressiva, or FOP. Host Aaron Lohr talks with three guests: Eileen M. Shore, PhD, Cali and Weldon Research Professor in FOP and co-director of the Center for Research in FOP and Related Disorders at the University of Pennsylvania School of Medicine; Elisabeth Marelise W. Eekhoff, MD, PhD, endocrinologist, principal investigator, and medical specialist at Amsterdam University Medical Center in the Netherlands; and Michelle Davis, executive director of the International Fibrodysplasia Ossificans Progressiva Association. This episode is certified for 0.5 American Medical Association Physician’s Recognition Award (AMA PRA) Category 1™ credits and 0.5 American Board of Internal Medicine Maintenance of Certification (ABIM MOC) points. If you want those credits and points, you will have to browse to the Endocrine Society’s Center for Learning, take a pre-test, listen to this episode there, then take a post-test. This episode is supported by an educational grant from Ipsen Biopharmaceuticals Inc. Show notes, including link to the Center for Learning, are available at https://www.endocrine.org/podcast/enp84-fibrodysplasia-ossificans-progressiva — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

We all know that a sedentary lifestyle is not healthy for anyone, but just how strongly is physical activity connected to lipid levels in childhood? Host Aaron Lohr talks with Andrew Agbaje, MD, PhD, a physician and pediatric clinical epidemiologist at the University of Eastern Finland. He has authored a study recently published in The Journal of Clinical Endocrinology & Metabolism titled, “Associations of Sedentary Time and Physical Activity From Childhood With Lipids: A 13-Year Mediation and Temporal Study.” Show notes are available at https://www.endocrine.org/podcast/enp83-sedentary-time-and-physical-activity-effects-on-childhood-lipid-levels — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, we learn about endocrine-disrupting chemicals known as perfluoroalkyl and polyfluoroalkyl substances (PFAS), which break down so slowly that they have been called “forever chemicals.” Where can PFAS be found? What exactly is their effect on human health? What are manufacturers doing to limit exposure, and is it enough? Host Aaron Lohr talks with Benson T. Akingbemi, PhD, professor of anatomy and developmental biology at Auburn University. Dr. Akingbemi and colleagues recently published an article on PFAS in the journal Endocrinology titled, “Legacy and Emerging Perfluoroalkyl and Polyfluoroalkyl Substances Regulate Steroidogenesis in the Male Gonad.” Show notes are available at https://www.endocrine.org/podcast/enp82-pfas — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

According to the National Institutes of Health, more than two in five adults have obesity in the United States, and nearly one in three is overweight. To equip health care practitioners with the resources they need to treat patients with obesity, the Endocrine Society recently held its innaugual obesity fellows program, an exclusive, application-based, educational activity for current fellows. The program covered a wealth of information, and host Aaron Lohr talks with Amy Rothberg, MD, DABOM, program chair and a clinical professor of internal medicine at the University of Michigan’s School of Public Health. If you weren’t able to attend the fellows program, we have a free series of on-demand lectures available online, and those are accredited. With thanks to Lilly USA LLC and Novo Nordisk for making both the obesity fellows program and this podcast episode possible through an unrestricted, educational grant. Show notes, including a link to the Endocrine Society Learning Center for earning ABIM points and AMA PRA Category 1 credits, are available at https://www.endocrine.org/podcast/enp81-obesity-fellows-program — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

We all know that sleep is important, but sometimes we just don’t get enough. We also know the normal side effects from lack of sleep, but are there other, metabolic, and neuronendocrine effects from short sleep that we don’t know about. Host Aaron Lohr talks about this with Iris CM Pelsma, an academic researcher at Leiden University Medical Center in the Netherlands. She and her colleagues presented a study earlier this year, at ENDO 2023, titled, “Metabolic and Neuroendocrine Adaptability Following One Night of Partial Sleep Restriction in Dutch Males.” Show notes are available at https://www.endocrine.org/podcast/enp80-metabolic-and-neuroendocrine-effects-of-short-sleep — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Today’s topic is type 1 diabetes. What are some of the biggest challenges facing us today when it comes to diagnosing and treating type 1 diabetes, and how can we meet those challenges? Host Aaron Lohr talks with Irl Hirsch, MD, from the UW Diabetes Institute at the University of Washington. Dr. Hirsch and Davida Kruger, NP, from Henry Ford Health in Detroit co-chaired the Endocrine Society’s type 1 diabetes fellows series. That program and this podcast episode were both made possible by unrestricted, educational grants from Abbott Diabetes Care Inc., CeQur Corp., Dexcom, Insulet, JDRF, Lilly USA LLC, MannKind Corp., Novo Nordisk, Prevention Bio, Vertex, and Tandem Diabetes Care. Show notes are available at https://www.endocrine.org/podcast/enp79-type-1-diabetes-update — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast